3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy. (September 2015)

• Record Type: Journal Article
• Authors: Garon, E.B.; Scagliotti, G.V.; Gautschi, O.; Reck, M.; Thomas, M.; Docampo, L.I.; Kalofonos, H.; Kim, J.H.; Gans, S.; Brustugun, O.T.; Orlov, S.V.; Ferry, D.; Melemed, A.; Carter, G.C.; Zimmermann, A.H.; Treat, J.A.; Alexandris, E.; Lee, P.; Socinski, M.A.; Perol, M.
• Is Part Of: European journal of cancer. Volume 51:(2015)Supplement 3
• Page Start: S621
• Publication Date: 2015-09
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(16)31714-2
• Languages: English
• ISSNs: 0959-8049